Trial Profile
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Letrozole
- Indications Breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics
- Acronyms MONALEESA-1
- Sponsors Novartis Pharmaceuticals
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 10/09/2014), according to European Clinical Trials Database record.
- 18 Aug 2016 This trial has been completed in France as per European Clinical Trials Database record.
- 31 Dec 2015 Status changed from completed to discontinued, according to ClinicalTrials.gov record.